{"gene":"FMO2","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":1998,"finding":"The major human FMO2 allele encodes a truncated, catalytically inactive polypeptide lacking 64 C-terminal amino acids due to a C→T nonsense mutation at codon 472; heterologous expression confirmed the truncated protein is enzymatically inactive.","method":"cDNA isolation, sequence analysis, heterologous expression (functional assay)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct heterologous expression with functional assay, sequence-confirmed mechanism, replicated by multiple subsequent studies","pmids":["9804831"],"is_preprint":false},{"year":1992,"finding":"Human FMO2 encodes a 558-amino-acid NADPH-dependent flavoenzyme with conserved FAD- and NADP-binding sites; the gene maps to human chromosome 1 and is a single-copy gene.","method":"cDNA cloning, sequence analysis, Southern blot, PCR-based chromosomal mapping","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (sequencing, Southern blot, chromosomal mapping), foundational characterization replicated by later work","pmids":["1417778"],"is_preprint":false},{"year":1994,"finding":"Rabbit FMO2 expressed in E. coli catalyzes sulfoxidation of alkyl p-tolyl sulfides with high substrate affinity (Km <10 µM) and unique prochiral stereoselectivity distinguishable from FMO1 and FMO3; FMO5 did not produce quantifiable sulfoxide metabolites under the same conditions.","method":"cDNA expression in E. coli, kinetic assays, stereochemical product analysis","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with kinetic and stereochemical characterization of expressed isoforms","pmids":["8203899"],"is_preprint":false},{"year":1996,"finding":"FMO2 and FMO5 genes are both located on human chromosome 1q, consistent with clustering of the entire FMO gene family in this chromosomal region.","method":"PCR analysis of human-rodent somatic cell hybrid panel","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — PCR-based chromosomal mapping, single lab, consistent with prior FMO1/3/4 mapping","pmids":["8786146"],"is_preprint":false},{"year":1997,"finding":"Rhesus macaque lung microsomes express an FMO2 ortholog; a full-length cDNA (535 aa) with conserved FAD- and NADP-binding sites was cloned, and FMO2 mRNA is expressed in lung but not liver or kidney.","method":"Lung cDNA library screening, Northern blot, immunochemical cross-reactivity","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cDNA cloning plus Northern blot tissue distribution, single lab","pmids":["9061021"],"is_preprint":false},{"year":2000,"finding":"A minority FMO2 allele (1414C, encoding Gln472) present at ~13% frequency in African-Americans produces full-length immunoreactive FMO2 protein detectable by Western blot in lung microsomes; heterozygotes express protein but activity was below detection limit under assay conditions.","method":"Genotyping, Western blot of pulmonary microsomes, FMO activity assay","journal":"Toxicology and applied pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — protein detection by Western blot correlated with genotype, single lab","pmids":["11042094"],"is_preprint":false},{"year":2001,"finding":"Baculovirus-expressed full-length monkey FMO2 (mFMO2-535) is catalytically active in N- and S-oxygenation assays with pH optimum 9.5, whereas the 3'-truncated form (mFMO2-471) is correctly membrane-targeted but shows no detectable N- or S-oxygenation activity.","method":"Baculovirus expression, N-oxygenation and S-oxygenation activity assays, membrane fractionation","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted enzymatic activity with truncation control, multiple substrate assays, single lab","pmids":["11302936"],"is_preprint":false},{"year":2002,"finding":"Laboratory rat FMO2 encodes a truncated protein of 432 residues due to a double deletion causing a frameshift and premature stop codon; heterologous expression confirmed this truncated protein is catalytically inactive.","method":"cDNA isolation, sequence analysis, heterologous expression, functional assay, Western blot","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct expression with confirmed loss of catalytic activity, sequence-verified mechanism","pmids":["11906197"],"is_preprint":false},{"year":2009,"finding":"FMO2.1 variant S195L shows a ~12-fold increase in Km for NADPH (disrupting NADPH interaction based on structural modeling), thermal instability reversed by NADPH, and loss of activity with cholate; variant N413K retains wild-type activity pattern but shows increased Vmax and kcat.","method":"Heterologous expression, sulfoxygenation kinetic assays, NADPH Km determination, thermal stability assay, structural modeling","journal":"Drug metabolism and disposition","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinetic characterization of expressed variants, single lab, structural modeling but no crystal structure","pmids":["19420133"],"is_preprint":false},{"year":2015,"finding":"Functional human FMO2 expressed in E. coli whole-cell biocatalysts catalyzes selective N-oxidation of trifluoperazine to its N1-oxide and oxidizes propranolol; C-terminal truncations abolish solubility without yielding soluble protein but affect recombinant protein levels.","method":"E. coli recombinant expression, whole-cell biotransformation assay, substrate screening","journal":"Microbial cell factories","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro/whole-cell catalytic assay with product characterization, single lab","pmids":["26062974"],"is_preprint":false},{"year":2023,"finding":"FMO2 directly interacts with SREBP1 (at amino acids 217–296 of SREBP1) and competitively inhibits SCAP binding to SREBP1, thereby blocking ER-to-Golgi translocation of SREBP1 and its subsequent proteolytic activation, suppressing de novo lipogenesis; this protective function is independent of FMO2 enzymatic activity.","method":"Co-IP, pulldown, hepatocyte-specific and global KO/OE mouse models, RNA sequencing, functional lipogenesis assays","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP defining binding domain, genetic KO/OE with clear phenotypic rescue, multiple orthogonal methods, single lab but comprehensive","pmids":["37874228"],"is_preprint":false},{"year":2025,"finding":"FMO2 localizes to mitochondria-associated ER membranes (MAMs) in cardiomyocytes, where it binds IP3R2 as part of the IP3R2-Grp75-VDAC1 complex, maintaining ER-mitochondria contact and regulating mitochondrial Ca2+ transfer for bioenergetics; FMO2 deletion worsens and overexpression prevents pathological cardiac hypertrophy.","method":"MAM-targeted mass spectrometry, Co-IP, cardiac-specific KO/OE mouse models (AAV9), Ca2+ imaging, neonatal cardiomyocyte culture, synthetic peptide rescue","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — mass spectrometry-identified MAM localization, Co-IP of complex, genetic KO/OE with phenotypic rescue, multiple orthogonal methods","pmids":["40489543"],"is_preprint":false},{"year":2025,"finding":"FMO2 in cancer-associated fibroblasts promotes CCL19 expression by competitively binding GYS1 with PJA1, thereby preventing PJA1-mediated proteasomal degradation of GYS1, which in turn activates NF-κB/p65-mediated CCL19 transcription and promotes tertiary lymphoid structure formation and CD8+ T cell infiltration.","method":"Co-IP (competitive binding), mouse orthotopic HCC models, coculture system, CyTOF, single-cell RNA sequencing, spatial transcriptomics","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for competitive binding, in vivo models with mechanistic follow-up, single lab","pmids":["40316306"],"is_preprint":false},{"year":2025,"finding":"FMO2 in endothelial cells promotes angiogenesis by regulating N-acetylornithine levels; N-acetylornithine inactivates NOTCH1 expression through ATF3-mediated transcriptional regulation.","method":"Single-cell transcriptome analysis, metabolomics, EC-specific genetic rescue in FMO2 ablation models, retinal and ischemic disease models","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — metabolomics-linked pathway, genetic EC rescue, single lab with multiple models","pmids":["41053533"],"is_preprint":false},{"year":2025,"finding":"FMO2 protects cardiomyocytes against doxorubicin-induced cardiotoxicity by stabilizing chromatin-associated XLF (XRCC4-like factor), thereby promoting DNA repair; FMO2 KO exacerbates DOX-induced damage and cardiomyocyte-specific overexpression is protective.","method":"Genetic KO and cardiomyocyte-specific OE mouse models, transcriptome profiling, chromatin analysis, adenoviral KD/OE in neonatal rat ventricular myocytes, xenograft antitumor efficacy model","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic models with mechanistic chromatin/DNA repair follow-up, single lab","pmids":["40752568"],"is_preprint":false},{"year":2024,"finding":"Exercise training upregulates cardiac FMO2 via AMPK activation; AMPK activates KLF4 as a transcriptional mediator of FMO2 expression, and FMO2 is required (AAV9 knockdown abrogates protection) to protect the heart against sympathetic overactivation-induced cardiac dysfunction and fibrosis.","method":"AAV9-mediated FMO2 knockdown in vivo, AMPK activation experiments, KLF4 transcription factor analysis","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic loss-of-function with defined pathway (AMPK-KLF4-FMO2), single lab","pmids":["39491669"],"is_preprint":false},{"year":2025,"finding":"CELF4, an RNA-binding protein induced by TGF-β1 in cardiac fibroblasts, binds the 3'UTR of FMO2 mRNA and suppresses FMO2 expression, thereby enhancing Smad2/3 phosphorylation and promoting cardiac fibrosis; CELF4 depletion elevates FMO2 and attenuates fibrosis.","method":"RNA pulldown, luciferase assay, RIP assay, TAC mouse model, TGF-β1-stimulated cardiac fibroblasts, Western blot","journal":"BMC cardiovascular disorders","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA pulldown and luciferase confirming 3'UTR binding, in vivo TAC model, single lab","pmids":["40610856"],"is_preprint":false},{"year":2025,"finding":"CELF1 binds FMO2 mRNA 3'UTR and promotes FMO2 mRNA decay, suppressing FMO2 expression post-MI; CELF1 silencing upregulates FMO2 and improves cardiac remodeling, whereas FMO2 overexpression rescues ECM deposition.","method":"RIP assay, RNA pulldown, actinomycin D mRNA stability assay, lentiviral OE/KD, LAD ligation MI mouse model","journal":"Cardiovascular toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP and RNA pulldown confirming mRNA binding and decay, in vivo rescue model, single lab","pmids":["40021568"],"is_preprint":false}],"current_model":"Human FMO2 is an NADPH-dependent flavoenzyme (FAD- and NADP-binding sites conserved) that, when full-length (Q472), catalyzes N- and S-oxygenation of drugs and xenobiotics primarily in the lung; the major human allele carries a C472X nonsense mutation producing a catalytically inactive truncated protein, while active enzyme is found only in individuals of African or Hispanic ancestry carrying the FMO2*1 allele. Beyond its classical xenobiotic-metabolizing role, FMO2 has enzyme-activity-independent functions: it binds SREBP1 (aa 217–296) to competitively block SCAP interaction and prevent ER-to-Golgi SREBP1 translocation and lipogenic gene activation; it localizes to mitochondria-associated ER membranes (MAMs) where it forms part of the IP3R2-Grp75-VDAC1 complex to maintain ER-mitochondria Ca²⁺ transfer and bioenergetics; it stabilizes chromatin-associated XLF to promote DNA repair in cardiomyocytes; and its expression is transcriptionally regulated by the AMPK-KLF4 axis and post-transcriptionally suppressed by RNA-binding proteins CELF1 and CELF4 acting on its 3'UTR."},"narrative":{"mechanistic_narrative":"FMO2 is an NADPH-dependent, FAD-containing flavoenzyme that classically catalyzes N- and S-oxygenation of drugs and xenobiotics, with characteristic high substrate affinity and prochiral stereoselectivity distinct from other FMO isoforms [PMID:8203899, PMID:1417778]. In most humans this canonical activity is lost because the major allele carries a C472X nonsense mutation that truncates 64 C-terminal residues and abolishes catalysis, while only a minority allele (Gln472) found at appreciable frequency in individuals of African ancestry produces full-length, catalytically active enzyme [PMID:9804831, PMID:11042094]; reconstitution of full-length versus 3'-truncated orthologs confirms that the C-terminus is required for oxygenation activity despite correct membrane targeting [PMID:11302936]. Beyond xenobiotic metabolism, FMO2 has emerged as a multifunctional protein with enzyme-activity-independent scaffolding roles: it binds SREBP1 (residues 217–296) to competitively block SCAP engagement, preventing ER-to-Golgi SREBP1 translocation and proteolytic activation and thereby suppressing de novo lipogenesis [PMID:37874228]. In cardiomyocytes FMO2 localizes to mitochondria-associated ER membranes, where it joins the IP3R2-Grp75-VDAC1 complex to sustain ER-mitochondria Ca²⁺ transfer and bioenergetics, and its loss exacerbates while its overexpression prevents pathological cardiac hypertrophy [PMID:40489543]. Additional protective cardiac functions include stabilization of chromatin-associated XLF to promote DNA repair against doxorubicin toxicity [PMID:40752568], and its cardiac expression is controlled by an AMPK-KLF4 transcriptional axis [PMID:39491669] and by post-transcriptional suppression through the RNA-binding proteins CELF1 and CELF4 acting on its 3'UTR [PMID:40610856, PMID:40021568].","teleology":[{"year":1992,"claim":"Establishing FMO2 as a discrete flavoenzyme gene with defined cofactor-binding architecture provided the molecular foundation for studying its catalytic chemistry.","evidence":"cDNA cloning, sequence analysis, Southern blot and chromosomal mapping of human FMO2","pmids":["1417778"],"confidence":"High","gaps":["No enzymatic activity demonstrated in this study","Tissue distribution and substrate range not yet defined"]},{"year":1994,"claim":"Reconstitution of the active enzyme defined FMO2's distinctive catalytic signature, distinguishing it kinetically and stereochemically from sibling FMO isoforms.","evidence":"Rabbit FMO2 expressed in E. coli, sulfoxidation kinetics and stereochemical product analysis","pmids":["8203899"],"confidence":"High","gaps":["Ortholog rather than human enzyme","Physiological substrates in vivo not established"]},{"year":1998,"claim":"Discovery that the predominant human allele is a C472X truncation explained why most humans lack functional pulmonary FMO2, reframing the gene as a polymorphic pseudo-enzyme in most populations.","evidence":"cDNA isolation, sequence analysis, heterologous expression with functional assay","pmids":["9804831"],"confidence":"High","gaps":["Functional consequence of activity loss for human physiology unaddressed","Frequency of active allele across populations not quantified here"]},{"year":2001,"claim":"Side-by-side expression of full-length versus truncated orthologs showed the C-terminus is required for catalysis but not membrane targeting, localizing the functional defect of the truncated allele.","evidence":"Baculovirus expression of full-length and truncated monkey FMO2, N-/S-oxygenation assays, membrane fractionation","pmids":["11302936"],"confidence":"High","gaps":["Monkey ortholog","Structural basis for C-terminal requirement not resolved"]},{"year":2009,"claim":"Kinetic dissection of natural FMO2.1 variants mapped residues critical for NADPH binding and thermal stability, linking specific positions to catalytic competence.","evidence":"Heterologous expression of S195L and N413K variants, NADPH Km, thermal stability assays, structural modeling","pmids":["19420133"],"confidence":"Medium","gaps":["No crystal structure","In vivo consequences of variants not tested"]},{"year":2023,"claim":"Identification of FMO2 binding SREBP1 to block SCAP-dependent activation revealed an enzyme-independent role in restraining lipogenesis, redefining FMO2 as a scaffold/regulator rather than only a metabolizing enzyme.","evidence":"Reciprocal Co-IP/pulldown defining binding domain, hepatocyte and global KO/OE mouse models, RNA-seq, lipogenesis assays","pmids":["37874228"],"confidence":"High","gaps":["Whether catalytic-dead human variants retain this function untested","Structural basis of SCAP competition not solved"]},{"year":2024,"claim":"Defining the AMPK-KLF4 axis as a driver of cardiac FMO2 expression connected exercise/energy-sensing signaling to FMO2-dependent cardioprotection.","evidence":"AAV9 FMO2 knockdown in vivo, AMPK activation, KLF4 transcription factor analysis","pmids":["39491669"],"confidence":"Medium","gaps":["Direct KLF4 binding to FMO2 promoter not detailed","Downstream cardioprotective effector of FMO2 not defined in this study"]},{"year":2025,"claim":"MAM localization within the IP3R2-Grp75-VDAC1 complex established FMO2 as a structural organizer of ER-mitochondria Ca2+ transfer controlling cardiac bioenergetics and hypertrophy.","evidence":"MAM-targeted mass spectrometry, Co-IP, cardiac KO/OE (AAV9), Ca2+ imaging, peptide rescue","pmids":["40489543"],"confidence":"High","gaps":["Direct binding interface within the complex not mapped","Whether activity contributes is not separated from scaffolding"]},{"year":2025,"claim":"Demonstration that FMO2 stabilizes chromatin-associated XLF to promote DNA repair added a genome-protective mechanism underlying its defense against cardiotoxic stress.","evidence":"Genetic KO and cardiomyocyte OE mouse models, chromatin analysis, adenoviral KD/OE in NRVMs, xenograft model","pmids":["40752568"],"confidence":"Medium","gaps":["Mechanism of XLF stabilization (direct binding vs indirect) not resolved","Generalizability beyond cardiomyocytes unknown"]},{"year":2025,"claim":"Identification of CELF1 and CELF4 as 3'UTR-binding suppressors of FMO2 established post-transcriptional control as a key node setting FMO2 levels in cardiac disease.","evidence":"RIP, RNA pulldown, luciferase, mRNA stability assays, TAC and LAD-ligation MI mouse models","pmids":["40610856","40021568"],"confidence":"Medium","gaps":["Precise 3'UTR binding sites not mapped to nucleotide resolution","Interplay between transcriptional (KLF4) and post-transcriptional control unexamined"]},{"year":2025,"claim":"Roles in cancer-associated fibroblasts and endothelial cells extended FMO2 function to tumor immunity and angiogenesis through competitive protein binding and metabolite regulation.","evidence":"Co-IP competitive binding (GYS1/PJA1), metabolomics (N-acetylornithine), orthotopic HCC and retinal/ischemic models, scRNA-seq, spatial transcriptomics","pmids":["40316306","41053533"],"confidence":"Medium","gaps":["Single-lab findings without independent replication","Whether enzymatic activity underlies metabolite changes not cleanly separated from scaffolding"]},{"year":null,"claim":"It remains unresolved how FMO2's classical oxygenase activity relates mechanistically to its multiple enzyme-independent scaffolding functions, and whether the catalytically inactive human truncation retains any of these moonlighting roles.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking catalytic and scaffolding states","Human truncated allele not tested in the non-catalytic interaction assays","Tissue-specific partner repertoire incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[1,2,6]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,6,9]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[10,12]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[10,11]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[10,11]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[11]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[2,10]},{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[0,9]}],"complexes":["IP3R2-Grp75-VDAC1 MAM complex"],"partners":["SREBF1","SCAP","ITPR2","GYS1","PJA1","CELF1","CELF4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P31512","full_name":"Dimethylaniline monooxygenase [N-oxide-forming] 4","aliases":["Dimethylaniline oxidase 4","Hepatic flavin-containing monooxygenase 4","FMO 4"],"length_aa":558,"mass_kda":63.3,"function":"This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides","subcellular_location":"Microsome membrane; Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/P31512/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FMO2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FMO2","total_profiled":1310},"omim":[{"mim_id":"603957","title":"FLAVIN-CONTAINING DIMETHYLANILINE MONOOXYGENASE 5; FMO5","url":"https://www.omim.org/entry/603957"},{"mim_id":"603955","title":"FLAVIN-CONTAINING DIMETHYLANILINE MONOOXYGENASE 2; FMO2","url":"https://www.omim.org/entry/603955"},{"mim_id":"136131","title":"FLAVIN-CONTAINING DIMETHYLANILINE MONOOXYGENASE 4; FMO4","url":"https://www.omim.org/entry/136131"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":65.4},{"tissue":"blood vessel","ntpm":93.7},{"tissue":"lung","ntpm":74.8}],"url":"https://www.proteinatlas.org/search/FMO2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P31512","domains":[{"cath_id":"3.50.50.60","chopping":"5-152_333-418","consensus_level":"high","plddt":95.3283,"start":5,"end":418},{"cath_id":"3.50.50.60","chopping":"156-328","consensus_level":"high","plddt":94.9161,"start":156,"end":328}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P31512","model_url":"https://alphafold.ebi.ac.uk/files/AF-P31512-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P31512-F1-predicted_aligned_error_v6.png","plddt_mean":91.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FMO2","jax_strain_url":"https://www.jax.org/strain/search?query=FMO2"},"sequence":{"accession":"P31512","fasta_url":"https://rest.uniprot.org/uniprotkb/P31512.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P31512/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P31512"}},"corpus_meta":[{"pmid":"9804831","id":"PMC_9804831","title":"The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9804831","citation_count":104,"is_preprint":false},{"pmid":"11042094","id":"PMC_11042094","title":"Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans.","date":"2000","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11042094","citation_count":67,"is_preprint":false},{"pmid":"1417778","id":"PMC_1417778","title":"Cloning, primary sequence and chromosomal localization of human FMO2, a new member of the flavin-containing mono-oxygenase family.","date":"1992","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/1417778","citation_count":52,"is_preprint":false},{"pmid":"23583631","id":"PMC_23583631","title":"Hypoxia inducible factor-1 (HIF-1)-flavin containing monooxygenase-2 (FMO-2) signaling acts in silver nanoparticles and silver ion toxicity in the nematode, Caenorhabditis elegans.","date":"2013","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23583631","citation_count":38,"is_preprint":false},{"pmid":"8203899","id":"PMC_8203899","title":"Prochiral sulfoxidation as a probe for multiple forms of the microsomal flavin-containing monooxygenase: studies with rabbit FMO1, FMO2, FMO3, and FMO5 expressed in Escherichia coli.","date":"1994","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/8203899","citation_count":37,"is_preprint":false},{"pmid":"18234543","id":"PMC_18234543","title":"CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma--a pilot study.","date":"2008","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18234543","citation_count":36,"is_preprint":false},{"pmid":"11302936","id":"PMC_11302936","title":"Characterization of expressed full-length and truncated FMO2 from rhesus monkey.","date":"2001","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/11302936","citation_count":29,"is_preprint":false},{"pmid":"8786146","id":"PMC_8786146","title":"Localization of human flavin-containing monooxygenase genes FMO2 and FMO5 to chromosome 1q.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8786146","citation_count":27,"is_preprint":false},{"pmid":"15355885","id":"PMC_15355885","title":"Differences in FMO2*1 allelic frequency between Hispanics of Puerto Rican and Mexican descent.","date":"2004","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/15355885","citation_count":24,"is_preprint":false},{"pmid":"9061021","id":"PMC_9061021","title":"Pulmonary flavin-containing monooxygenase (FMO) in rhesus macaque: expression of FMO2 protein, mRNA and analysis of the cDNA.","date":"1997","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9061021","citation_count":22,"is_preprint":false},{"pmid":"37874228","id":"PMC_37874228","title":"FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1.","date":"2023","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/37874228","citation_count":20,"is_preprint":false},{"pmid":"15864117","id":"PMC_15864117","title":"Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics.","date":"2005","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/15864117","citation_count":20,"is_preprint":false},{"pmid":"11906197","id":"PMC_11906197","title":"The FMO2 gene of laboratory rats, as in most humans, encodes a truncated protein.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11906197","citation_count":17,"is_preprint":false},{"pmid":"26062974","id":"PMC_26062974","title":"Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis.","date":"2015","source":"Microbial cell factories","url":"https://pubmed.ncbi.nlm.nih.gov/26062974","citation_count":15,"is_preprint":false},{"pmid":"40316306","id":"PMC_40316306","title":"FMO2+ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma.","date":"2025","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40316306","citation_count":14,"is_preprint":false},{"pmid":"40489543","id":"PMC_40489543","title":"FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interaction With IP3R2-Grp75-VDAC1.","date":"2025","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/40489543","citation_count":10,"is_preprint":false},{"pmid":"8971137","id":"PMC_8971137","title":"Structural characteristics of flavin-containing monooxygenase genes one and two (FMO1 and FMO2).","date":"1996","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/8971137","citation_count":9,"is_preprint":false},{"pmid":"19420133","id":"PMC_19420133","title":"Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.","date":"2009","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/19420133","citation_count":8,"is_preprint":false},{"pmid":"15454729","id":"PMC_15454729","title":"Identification and characterization of the FMO2 gene in Rattus norvegicus: a good model to study metabolic and toxicological consequences of the FMO2 polymorphism.","date":"2004","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/15454729","citation_count":6,"is_preprint":false},{"pmid":"36318393","id":"PMC_36318393","title":"The FMO2 analysis of the ligand-receptor binding energy: the Biscarbene-Gold(I)/DNA G-Quadruplex case study.","date":"2022","source":"Journal of computer-aided molecular design","url":"https://pubmed.ncbi.nlm.nih.gov/36318393","citation_count":5,"is_preprint":false},{"pmid":"28981537","id":"PMC_28981537","title":"An ancestral human genetic variant linked to an ancient disease: A novel association of FMO2 polymorphisms with tuberculosis (TB) in Ethiopian populations provides new insight into the differential ethno-geographic distribution of FMO2*1.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28981537","citation_count":5,"is_preprint":false},{"pmid":"37814902","id":"PMC_37814902","title":"Circ_MACF1 targets miR-421 to upregulate FMO2 to suppress paclitaxel resistance and malignant cellular behaviors in lung adenocarcinoma.","date":"2023","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37814902","citation_count":3,"is_preprint":false},{"pmid":"41053533","id":"PMC_41053533","title":"FMO2 Promotes Angiogenesis via Regulation of N-Acetylornithine.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41053533","citation_count":1,"is_preprint":false},{"pmid":"40752568","id":"PMC_40752568","title":"FMO2 expression confers cardioprotection in doxorubicin therapy while preserving antitumor activity.","date":"2025","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/40752568","citation_count":1,"is_preprint":false},{"pmid":"39491669","id":"PMC_39491669","title":"Exercise training attenuates cardiac dysfunction induced by excessive sympathetic activation through an AMPK-KLF4-FMO2 axis.","date":"2024","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/39491669","citation_count":1,"is_preprint":false},{"pmid":"40610856","id":"PMC_40610856","title":"CUGBP Elav-like family member 4 promotes cardiac remodeling through Inhibition of FMO2.","date":"2025","source":"BMC cardiovascular disorders","url":"https://pubmed.ncbi.nlm.nih.gov/40610856","citation_count":1,"is_preprint":false},{"pmid":"39867229","id":"PMC_39867229","title":"Perception of Enterococcus faecalis without infection induces fmo-2 in C. elegans.","date":"2025","source":"microPublication biology","url":"https://pubmed.ncbi.nlm.nih.gov/39867229","citation_count":1,"is_preprint":false},{"pmid":"40021568","id":"PMC_40021568","title":"CELF1 Promotes Post-myocardial Infarction Cardiac Remodeling Via Suppression of FMO2.","date":"2025","source":"Cardiovascular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/40021568","citation_count":0,"is_preprint":false},{"pmid":"41134904","id":"PMC_41134904","title":"Metabolic regulation of behavior by the intestinal enzyme FMO-2.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/41134904","citation_count":0,"is_preprint":false},{"pmid":"41702017","id":"PMC_41702017","title":"The 1 -Cys peroxiredoxin, PRDX-6, suppresses an NHR-49-dependent pro-survival response, including the Flavin monooxygenase, FMO-2, that protects against fungal and bacterial infection.","date":"2025","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/41702017","citation_count":0,"is_preprint":false},{"pmid":"42204289","id":"PMC_42204289","title":"snRNA-seq identifies Fmo2+ fibroblasts as drivers of hyperglycemic memory-induced cardiac injury.","date":"2026","source":"npj metabolic health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/42204289","citation_count":0,"is_preprint":false},{"pmid":"41960420","id":"PMC_41960420","title":"Mild mitochondrial impairment activates overlapping longevity pathways converging on the flavin-containing monooxygenase FMO-2.","date":"2026","source":"Frontiers in aging","url":"https://pubmed.ncbi.nlm.nih.gov/41960420","citation_count":0,"is_preprint":false},{"pmid":"41726866","id":"PMC_41726866","title":"Mild Mitochondrial Impairment Activates Overlapping Longevity Pathways Converging on the Flavin-Containing Monooxygenase FMO-2.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41726866","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":19458,"output_tokens":4197,"usd":0.060665,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12134,"output_tokens":3787,"usd":0.077673,"stage2_stop_reason":"end_turn"},"total_usd":0.138338,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"The major human FMO2 allele encodes a truncated, catalytically inactive polypeptide lacking 64 C-terminal amino acids due to a C→T nonsense mutation at codon 472; heterologous expression confirmed the truncated protein is enzymatically inactive.\",\n      \"method\": \"cDNA isolation, sequence analysis, heterologous expression (functional assay)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct heterologous expression with functional assay, sequence-confirmed mechanism, replicated by multiple subsequent studies\",\n      \"pmids\": [\"9804831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Human FMO2 encodes a 558-amino-acid NADPH-dependent flavoenzyme with conserved FAD- and NADP-binding sites; the gene maps to human chromosome 1 and is a single-copy gene.\",\n      \"method\": \"cDNA cloning, sequence analysis, Southern blot, PCR-based chromosomal mapping\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (sequencing, Southern blot, chromosomal mapping), foundational characterization replicated by later work\",\n      \"pmids\": [\"1417778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Rabbit FMO2 expressed in E. coli catalyzes sulfoxidation of alkyl p-tolyl sulfides with high substrate affinity (Km <10 µM) and unique prochiral stereoselectivity distinguishable from FMO1 and FMO3; FMO5 did not produce quantifiable sulfoxide metabolites under the same conditions.\",\n      \"method\": \"cDNA expression in E. coli, kinetic assays, stereochemical product analysis\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with kinetic and stereochemical characterization of expressed isoforms\",\n      \"pmids\": [\"8203899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"FMO2 and FMO5 genes are both located on human chromosome 1q, consistent with clustering of the entire FMO gene family in this chromosomal region.\",\n      \"method\": \"PCR analysis of human-rodent somatic cell hybrid panel\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PCR-based chromosomal mapping, single lab, consistent with prior FMO1/3/4 mapping\",\n      \"pmids\": [\"8786146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Rhesus macaque lung microsomes express an FMO2 ortholog; a full-length cDNA (535 aa) with conserved FAD- and NADP-binding sites was cloned, and FMO2 mRNA is expressed in lung but not liver or kidney.\",\n      \"method\": \"Lung cDNA library screening, Northern blot, immunochemical cross-reactivity\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cDNA cloning plus Northern blot tissue distribution, single lab\",\n      \"pmids\": [\"9061021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A minority FMO2 allele (1414C, encoding Gln472) present at ~13% frequency in African-Americans produces full-length immunoreactive FMO2 protein detectable by Western blot in lung microsomes; heterozygotes express protein but activity was below detection limit under assay conditions.\",\n      \"method\": \"Genotyping, Western blot of pulmonary microsomes, FMO activity assay\",\n      \"journal\": \"Toxicology and applied pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — protein detection by Western blot correlated with genotype, single lab\",\n      \"pmids\": [\"11042094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Baculovirus-expressed full-length monkey FMO2 (mFMO2-535) is catalytically active in N- and S-oxygenation assays with pH optimum 9.5, whereas the 3'-truncated form (mFMO2-471) is correctly membrane-targeted but shows no detectable N- or S-oxygenation activity.\",\n      \"method\": \"Baculovirus expression, N-oxygenation and S-oxygenation activity assays, membrane fractionation\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted enzymatic activity with truncation control, multiple substrate assays, single lab\",\n      \"pmids\": [\"11302936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Laboratory rat FMO2 encodes a truncated protein of 432 residues due to a double deletion causing a frameshift and premature stop codon; heterologous expression confirmed this truncated protein is catalytically inactive.\",\n      \"method\": \"cDNA isolation, sequence analysis, heterologous expression, functional assay, Western blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct expression with confirmed loss of catalytic activity, sequence-verified mechanism\",\n      \"pmids\": [\"11906197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FMO2.1 variant S195L shows a ~12-fold increase in Km for NADPH (disrupting NADPH interaction based on structural modeling), thermal instability reversed by NADPH, and loss of activity with cholate; variant N413K retains wild-type activity pattern but shows increased Vmax and kcat.\",\n      \"method\": \"Heterologous expression, sulfoxygenation kinetic assays, NADPH Km determination, thermal stability assay, structural modeling\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinetic characterization of expressed variants, single lab, structural modeling but no crystal structure\",\n      \"pmids\": [\"19420133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Functional human FMO2 expressed in E. coli whole-cell biocatalysts catalyzes selective N-oxidation of trifluoperazine to its N1-oxide and oxidizes propranolol; C-terminal truncations abolish solubility without yielding soluble protein but affect recombinant protein levels.\",\n      \"method\": \"E. coli recombinant expression, whole-cell biotransformation assay, substrate screening\",\n      \"journal\": \"Microbial cell factories\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro/whole-cell catalytic assay with product characterization, single lab\",\n      \"pmids\": [\"26062974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FMO2 directly interacts with SREBP1 (at amino acids 217–296 of SREBP1) and competitively inhibits SCAP binding to SREBP1, thereby blocking ER-to-Golgi translocation of SREBP1 and its subsequent proteolytic activation, suppressing de novo lipogenesis; this protective function is independent of FMO2 enzymatic activity.\",\n      \"method\": \"Co-IP, pulldown, hepatocyte-specific and global KO/OE mouse models, RNA sequencing, functional lipogenesis assays\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP defining binding domain, genetic KO/OE with clear phenotypic rescue, multiple orthogonal methods, single lab but comprehensive\",\n      \"pmids\": [\"37874228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FMO2 localizes to mitochondria-associated ER membranes (MAMs) in cardiomyocytes, where it binds IP3R2 as part of the IP3R2-Grp75-VDAC1 complex, maintaining ER-mitochondria contact and regulating mitochondrial Ca2+ transfer for bioenergetics; FMO2 deletion worsens and overexpression prevents pathological cardiac hypertrophy.\",\n      \"method\": \"MAM-targeted mass spectrometry, Co-IP, cardiac-specific KO/OE mouse models (AAV9), Ca2+ imaging, neonatal cardiomyocyte culture, synthetic peptide rescue\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mass spectrometry-identified MAM localization, Co-IP of complex, genetic KO/OE with phenotypic rescue, multiple orthogonal methods\",\n      \"pmids\": [\"40489543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FMO2 in cancer-associated fibroblasts promotes CCL19 expression by competitively binding GYS1 with PJA1, thereby preventing PJA1-mediated proteasomal degradation of GYS1, which in turn activates NF-κB/p65-mediated CCL19 transcription and promotes tertiary lymphoid structure formation and CD8+ T cell infiltration.\",\n      \"method\": \"Co-IP (competitive binding), mouse orthotopic HCC models, coculture system, CyTOF, single-cell RNA sequencing, spatial transcriptomics\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for competitive binding, in vivo models with mechanistic follow-up, single lab\",\n      \"pmids\": [\"40316306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FMO2 in endothelial cells promotes angiogenesis by regulating N-acetylornithine levels; N-acetylornithine inactivates NOTCH1 expression through ATF3-mediated transcriptional regulation.\",\n      \"method\": \"Single-cell transcriptome analysis, metabolomics, EC-specific genetic rescue in FMO2 ablation models, retinal and ischemic disease models\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — metabolomics-linked pathway, genetic EC rescue, single lab with multiple models\",\n      \"pmids\": [\"41053533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FMO2 protects cardiomyocytes against doxorubicin-induced cardiotoxicity by stabilizing chromatin-associated XLF (XRCC4-like factor), thereby promoting DNA repair; FMO2 KO exacerbates DOX-induced damage and cardiomyocyte-specific overexpression is protective.\",\n      \"method\": \"Genetic KO and cardiomyocyte-specific OE mouse models, transcriptome profiling, chromatin analysis, adenoviral KD/OE in neonatal rat ventricular myocytes, xenograft antitumor efficacy model\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic models with mechanistic chromatin/DNA repair follow-up, single lab\",\n      \"pmids\": [\"40752568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Exercise training upregulates cardiac FMO2 via AMPK activation; AMPK activates KLF4 as a transcriptional mediator of FMO2 expression, and FMO2 is required (AAV9 knockdown abrogates protection) to protect the heart against sympathetic overactivation-induced cardiac dysfunction and fibrosis.\",\n      \"method\": \"AAV9-mediated FMO2 knockdown in vivo, AMPK activation experiments, KLF4 transcription factor analysis\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic loss-of-function with defined pathway (AMPK-KLF4-FMO2), single lab\",\n      \"pmids\": [\"39491669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CELF4, an RNA-binding protein induced by TGF-β1 in cardiac fibroblasts, binds the 3'UTR of FMO2 mRNA and suppresses FMO2 expression, thereby enhancing Smad2/3 phosphorylation and promoting cardiac fibrosis; CELF4 depletion elevates FMO2 and attenuates fibrosis.\",\n      \"method\": \"RNA pulldown, luciferase assay, RIP assay, TAC mouse model, TGF-β1-stimulated cardiac fibroblasts, Western blot\",\n      \"journal\": \"BMC cardiovascular disorders\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA pulldown and luciferase confirming 3'UTR binding, in vivo TAC model, single lab\",\n      \"pmids\": [\"40610856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CELF1 binds FMO2 mRNA 3'UTR and promotes FMO2 mRNA decay, suppressing FMO2 expression post-MI; CELF1 silencing upregulates FMO2 and improves cardiac remodeling, whereas FMO2 overexpression rescues ECM deposition.\",\n      \"method\": \"RIP assay, RNA pulldown, actinomycin D mRNA stability assay, lentiviral OE/KD, LAD ligation MI mouse model\",\n      \"journal\": \"Cardiovascular toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP and RNA pulldown confirming mRNA binding and decay, in vivo rescue model, single lab\",\n      \"pmids\": [\"40021568\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Human FMO2 is an NADPH-dependent flavoenzyme (FAD- and NADP-binding sites conserved) that, when full-length (Q472), catalyzes N- and S-oxygenation of drugs and xenobiotics primarily in the lung; the major human allele carries a C472X nonsense mutation producing a catalytically inactive truncated protein, while active enzyme is found only in individuals of African or Hispanic ancestry carrying the FMO2*1 allele. Beyond its classical xenobiotic-metabolizing role, FMO2 has enzyme-activity-independent functions: it binds SREBP1 (aa 217–296) to competitively block SCAP interaction and prevent ER-to-Golgi SREBP1 translocation and lipogenic gene activation; it localizes to mitochondria-associated ER membranes (MAMs) where it forms part of the IP3R2-Grp75-VDAC1 complex to maintain ER-mitochondria Ca²⁺ transfer and bioenergetics; it stabilizes chromatin-associated XLF to promote DNA repair in cardiomyocytes; and its expression is transcriptionally regulated by the AMPK-KLF4 axis and post-transcriptionally suppressed by RNA-binding proteins CELF1 and CELF4 acting on its 3'UTR.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FMO2 is an NADPH-dependent, FAD-containing flavoenzyme that classically catalyzes N- and S-oxygenation of drugs and xenobiotics, with characteristic high substrate affinity and prochiral stereoselectivity distinct from other FMO isoforms [#2, #1]. In most humans this canonical activity is lost because the major allele carries a C472X nonsense mutation that truncates 64 C-terminal residues and abolishes catalysis, while only a minority allele (Gln472) found at appreciable frequency in individuals of African ancestry produces full-length, catalytically active enzyme [#0, #5]; reconstitution of full-length versus 3'-truncated orthologs confirms that the C-terminus is required for oxygenation activity despite correct membrane targeting [#6]. Beyond xenobiotic metabolism, FMO2 has emerged as a multifunctional protein with enzyme-activity-independent scaffolding roles: it binds SREBP1 (residues 217\\u2013296) to competitively block SCAP engagement, preventing ER-to-Golgi SREBP1 translocation and proteolytic activation and thereby suppressing de novo lipogenesis [#10]. In cardiomyocytes FMO2 localizes to mitochondria-associated ER membranes, where it joins the IP3R2-Grp75-VDAC1 complex to sustain ER-mitochondria Ca\\u00b2\\u207a transfer and bioenergetics, and its loss exacerbates while its overexpression prevents pathological cardiac hypertrophy [#11]. Additional protective cardiac functions include stabilization of chromatin-associated XLF to promote DNA repair against doxorubicin toxicity [#14], and its cardiac expression is controlled by an AMPK-KLF4 transcriptional axis [#15] and by post-transcriptional suppression through the RNA-binding proteins CELF1 and CELF4 acting on its 3'UTR [#16, #17].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Establishing FMO2 as a discrete flavoenzyme gene with defined cofactor-binding architecture provided the molecular foundation for studying its catalytic chemistry.\",\n      \"evidence\": \"cDNA cloning, sequence analysis, Southern blot and chromosomal mapping of human FMO2\",\n      \"pmids\": [\"1417778\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No enzymatic activity demonstrated in this study\", \"Tissue distribution and substrate range not yet defined\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Reconstitution of the active enzyme defined FMO2's distinctive catalytic signature, distinguishing it kinetically and stereochemically from sibling FMO isoforms.\",\n      \"evidence\": \"Rabbit FMO2 expressed in E. coli, sulfoxidation kinetics and stereochemical product analysis\",\n      \"pmids\": [\"8203899\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ortholog rather than human enzyme\", \"Physiological substrates in vivo not established\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery that the predominant human allele is a C472X truncation explained why most humans lack functional pulmonary FMO2, reframing the gene as a polymorphic pseudo-enzyme in most populations.\",\n      \"evidence\": \"cDNA isolation, sequence analysis, heterologous expression with functional assay\",\n      \"pmids\": [\"9804831\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of activity loss for human physiology unaddressed\", \"Frequency of active allele across populations not quantified here\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Side-by-side expression of full-length versus truncated orthologs showed the C-terminus is required for catalysis but not membrane targeting, localizing the functional defect of the truncated allele.\",\n      \"evidence\": \"Baculovirus expression of full-length and truncated monkey FMO2, N-/S-oxygenation assays, membrane fractionation\",\n      \"pmids\": [\"11302936\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Monkey ortholog\", \"Structural basis for C-terminal requirement not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Kinetic dissection of natural FMO2.1 variants mapped residues critical for NADPH binding and thermal stability, linking specific positions to catalytic competence.\",\n      \"evidence\": \"Heterologous expression of S195L and N413K variants, NADPH Km, thermal stability assays, structural modeling\",\n      \"pmids\": [\"19420133\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No crystal structure\", \"In vivo consequences of variants not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of FMO2 binding SREBP1 to block SCAP-dependent activation revealed an enzyme-independent role in restraining lipogenesis, redefining FMO2 as a scaffold/regulator rather than only a metabolizing enzyme.\",\n      \"evidence\": \"Reciprocal Co-IP/pulldown defining binding domain, hepatocyte and global KO/OE mouse models, RNA-seq, lipogenesis assays\",\n      \"pmids\": [\"37874228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether catalytic-dead human variants retain this function untested\", \"Structural basis of SCAP competition not solved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defining the AMPK-KLF4 axis as a driver of cardiac FMO2 expression connected exercise/energy-sensing signaling to FMO2-dependent cardioprotection.\",\n      \"evidence\": \"AAV9 FMO2 knockdown in vivo, AMPK activation, KLF4 transcription factor analysis\",\n      \"pmids\": [\"39491669\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct KLF4 binding to FMO2 promoter not detailed\", \"Downstream cardioprotective effector of FMO2 not defined in this study\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"MAM localization within the IP3R2-Grp75-VDAC1 complex established FMO2 as a structural organizer of ER-mitochondria Ca2+ transfer controlling cardiac bioenergetics and hypertrophy.\",\n      \"evidence\": \"MAM-targeted mass spectrometry, Co-IP, cardiac KO/OE (AAV9), Ca2+ imaging, peptide rescue\",\n      \"pmids\": [\"40489543\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding interface within the complex not mapped\", \"Whether activity contributes is not separated from scaffolding\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstration that FMO2 stabilizes chromatin-associated XLF to promote DNA repair added a genome-protective mechanism underlying its defense against cardiotoxic stress.\",\n      \"evidence\": \"Genetic KO and cardiomyocyte OE mouse models, chromatin analysis, adenoviral KD/OE in NRVMs, xenograft model\",\n      \"pmids\": [\"40752568\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of XLF stabilization (direct binding vs indirect) not resolved\", \"Generalizability beyond cardiomyocytes unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of CELF1 and CELF4 as 3'UTR-binding suppressors of FMO2 established post-transcriptional control as a key node setting FMO2 levels in cardiac disease.\",\n      \"evidence\": \"RIP, RNA pulldown, luciferase, mRNA stability assays, TAC and LAD-ligation MI mouse models\",\n      \"pmids\": [\"40610856\", \"40021568\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Precise 3'UTR binding sites not mapped to nucleotide resolution\", \"Interplay between transcriptional (KLF4) and post-transcriptional control unexamined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Roles in cancer-associated fibroblasts and endothelial cells extended FMO2 function to tumor immunity and angiogenesis through competitive protein binding and metabolite regulation.\",\n      \"evidence\": \"Co-IP competitive binding (GYS1/PJA1), metabolomics (N-acetylornithine), orthotopic HCC and retinal/ischemic models, scRNA-seq, spatial transcriptomics\",\n      \"pmids\": [\"40316306\", \"41053533\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab findings without independent replication\", \"Whether enzymatic activity underlies metabolite changes not cleanly separated from scaffolding\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how FMO2's classical oxygenase activity relates mechanistically to its multiple enzyme-independent scaffolding functions, and whether the catalytically inactive human truncation retains any of these moonlighting roles.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model linking catalytic and scaffolding states\", \"Human truncated allele not tested in the non-catalytic interaction assays\", \"Tissue-specific partner repertoire incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [1, 2, 6]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 6, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [10, 12]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [10, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2, 10]},\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [0, 9]}\n    ],\n    \"complexes\": [\n      \"IP3R2-Grp75-VDAC1 MAM complex\"\n    ],\n    \"partners\": [\n      \"SREBF1\",\n      \"SCAP\",\n      \"ITPR2\",\n      \"GYS1\",\n      \"PJA1\",\n      \"CELF1\",\n      \"CELF4\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}